TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
复制标题
DOI：
10.18632/oncotarget.14315
复制
发表时间：
2017-02-14
期刊：
影响因子：
--
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Wu J;Li S;Yang Y;Zhu S;Zhang M;Qiao Y;Liu YJ;Chen J
浆细胞样树突状细胞（pDCs）是自然产生的树突状细胞的一个独特子集，在病毒感染后通过toll样受体（TLR） 7和TLR9触发大量I型干扰素（ifn）的产生。最近的研究表明，pDCs的激活可以杀死黑色素瘤细胞。然而，活化的pDCs在乳腺癌中的作用仍有待确定。在本研究中，我们建立了乳腺癌小鼠模型，证实了活化的pDCs可以通过TRAIL和Granzyme b直接杀死乳腺肿瘤细胞，并证实了pDCs可以启动NK细胞和CD8+ T细胞的顺序活化，最终抑制乳腺肿瘤的生长。了解活化的pDCs在乳腺癌中的作用可能有助于开发新的策略来操纵pDCs的功能并诱导乳腺癌的抗肿瘤免疫。
Plasmacytoid dendritic cells (pDCs) are a unique subset of naturally occurring dendritic cells, which triggers the production of large amounts of type I interferons (IFNs) after viral infections through Toll-like receptor (TLR) 7 and TLR9. Recent studies have demonstrated that the activation of pDCs kills melanoma cells. However, the role of activated pDCs in breast cancer remains to be determined. In the present study, we generated mouse models of breast cancer and demonstrated that activated pDCs can directly kill breast tumor cells through TRAIL and Granzyme B. Furthermore, we established that pDCs initiate the sequential activation of NK cells and CD8+ T cells, and ultimately inhibit breast tumor growth. Understanding the role of activated pDCs in breast cancer may help to develop new strategies for manipulating the function of pDCs and induce anti-tumor immunity in breast cancer.